Sunvozertinib Tablets 150 mg, 200 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 150 mg, 200 mg

Reference Brands: Zegfrovy (Dizal Pharmaceutical)

Category: Oncology Cancer Care

Sunvozertinib (Zegfrovy, Dizal) is an oral EGFR inhibitor for non-small cell lung cancer with EGFR exon 20 insertion mutations, approved in China in 2023 and by the US FDA in July 2025. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.

Product Description:

Sunvozertinib is an irreversible EGFR tyrosine kinase inhibitor built to block EGFR with exon 20 insertion mutations. These mutations, found in a small share of EGFR-mutant lung cancers, do not respond to standard EGFR tablets such as gefitinib, erlotinib or osimertinib. It is taken once a day; the US label dose is 200 mg.

China approved sunvozertinib in August 2023, and the US FDA granted accelerated approval as Zegfrovy in July 2025 for adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertions whose disease progressed on or after platinum chemotherapy. A test confirming the mutation is needed. It is supplied as 150 mg and 200 mg tablets.

Sourcing and licensing notes. Sunvozertinib is patented and made only by Dizal; there is no generic. The other oral option for this mutation, mobocertinib, has been withdrawn, and amivantamab is an infusion. We handle authorised-supply enquiries and connect developers and licensees interested in the molecule ahead of patent expiry.